Balyasny Asset Management’s Exact Sciences EXAS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-5,500
Closed -$559K 3072
2025
Q4
$559K Buy
+5,500
New +$442K ﹤0.01% 2477
2025
Q3
Sell
-238,000
Closed -$12.6M 3058
2025
Q2
$12.6M Buy
+238,000
New +$12.1M 0.02% 857
2025
Q1
Sell
-4,900
Closed -$275K 2928
2024
Q4
$275K Sell
4,900
-49,800
-91% -$3.1M ﹤0.01% 2425
2024
Q3
$3.73M Buy
+54,700
New +$3.09M 0.01% 1401
2024
Q2
Sell
-70,500
Closed -$4.87M 2721
2024
Q1
$4.87M Buy
+70,500
New +$4.46M 0.01% 1232
2022
Q4
Sell
-277,000
Closed -$9M 2907
2022
Q3
$9M Sell
277,000
-64,900
-19% -$2.68M 0.03% 734
2022
Q2
$13.5M Buy
341,900
+176,800
+107% +$9.45M 0.04% 551
2022
Q1
$11.5M Buy
165,100
+57,300
+53% +$4.19M 0.04% 647
2021
Q4
$8.39M Buy
107,800
+89,300
+483% +$7.88M 0.03% 690
2021
Q3
$1.77M Buy
+18,500
New +$1.95M 0.01% 1173
2019
Q4
Sell
-50,000
Closed -$4.52M 1252
2019
Q3
$4.52M Buy
50,000
+25,000
+100% +$2.85M 0.03% 567
2019
Q2
$2.89M Sell
25,000
-137,000
-85% -$13.8M 0.02% 775
2019
Q1
$14M Buy
+162,000
New +$13.8M 0.09% 305
2018
Q1
Sell
-50,000
Closed -$2.63M 2048
2017
Q4
$2.63M Buy
+50,000
New +$2.67M 0.01% 1059

Other funds holding EXAS

Balyasny Asset Management's EXAS Position: Q1 2026 in Review

Balyasny Asset Management sold out of Exact Sciences (EXAS) in Q1 2026, closing a stake of 4,089,977 shares — an estimated $415M sold.

Balyasny Asset Management first reported a position in EXAS in Q4 2015 and held it in 23 quarters. The position peaked at $415M in Q4 2025. 7 funds tracked by Wall St. Rank hold EXAS as of Q1 2026.

  • Balyasny Asset Management reported no remaining Exact Sciences position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 4,089,977 Exact Sciences shares in Q1 2026, an estimated $415M.
  • Balyasny Asset Management first reported a position in Exact Sciences in Q4 2015 and held it in 23 quarters.
  • Balyasny Asset Management's Exact Sciences position peaked at $415M in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Exact Sciences as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.